Veraxa Biotech is trading 5.8% down at $1.13 in after-hours, with no clear company-specific or broad-market catalyst verified. - The regular-session close was $1.20; recent sessions have been volatile, but no verified volume or trading-activity details are available. - On October 13, Veraxa announced early BiTAC-ADC proof-of-concept results, including tumor regression in a breast-cancer model. - The release did not report an after-hours market reaction, and available evidence does not establish that the positive research update explains the decline.